News
Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
StockStory.org on MSN14h
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...
Science reported that the National Institutes of Health (NIH) director, Jay Bhattacharya, dismissed all members of the agency’s top external advisory body, the Advisory Committee to the Director (ACD) ...
Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.
Explore more
In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile ...
Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...
Firms like Moderna that are rapidly adopting AI and will have a higher mix of AI software robots to humans in the future ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results